Prognostic Value and Clinical Implication of Lymph Node-to-Primary Tumor SUV Ratio in Node-Positive Hypopharyngeal Squamous Cell Carcinoma Treated With Radiotherapy With or Without Chemotherapy.

IF 9.6 3区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Clinical Nuclear Medicine Pub Date : 2025-01-01 Epub Date: 2024-10-17 DOI:10.1097/RLU.0000000000005544
Wing-Keen Yap, Chia-Hsin Lin, Ken-Hao Hsu, Shin-Nan Lin, Huan-Chun Lin, Kai-Ping Chang, Chung-Jan Kang, Yu-Feng Hu, Ming-Chieh Shih, Tsung-You Tsai
{"title":"Prognostic Value and Clinical Implication of Lymph Node-to-Primary Tumor SUV Ratio in Node-Positive Hypopharyngeal Squamous Cell Carcinoma Treated With Radiotherapy With or Without Chemotherapy.","authors":"Wing-Keen Yap, Chia-Hsin Lin, Ken-Hao Hsu, Shin-Nan Lin, Huan-Chun Lin, Kai-Ping Chang, Chung-Jan Kang, Yu-Feng Hu, Ming-Chieh Shih, Tsung-You Tsai","doi":"10.1097/RLU.0000000000005544","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>The aim of this was to evaluate the prognostic significance of the nodal-to-primary tumor SUV max ratio (NTR) in patients with node-positive hypopharyngeal squamous cell carcinoma (HPSCC) treated with radiotherapy with or without concurrent chemotherapy. The study aims to enhance prognostic accuracy by incorporating NTR into the American Joint Committee on Cancer (AJCC) staging system.</p><p><strong>Patients and methods: </strong>This retrospective study included 191 patients with biopsy-proven node-positive HPSCC treated from 2005 to 2013. NTR was calculated as the ratio of SUV max of metastatic lymph nodes to the primary tumor's SUV max . Survival analyses were conducted using Cox regression models and Kaplan-Meier analysis. Receiver operating characteristic analysis compared the prognostic performance of the modified and AJCC staging systems.</p><p><strong>Results: </strong>The median follow-up was 8.27 years, with 135 deaths (70.7%). High NTR (≥0.63) was significantly associated with worse overall survival (OS) and was an independent prognostic factor in multivariable analysis (adjusted hazards ratio [HR] = 1.63, P = 0.007). Median OS for high NTR was 17.4 months, compared with 75.2 months for low NTR. High NTR significantly predicted worse OS within AJCC stage IVA patients (HR = 6.09, P = 0.014). Patients in modified stage IVA (AJCC stage IVA with low NTR) had significantly longer OS than those in modified stage IVB (AJCC stage IVA with high NTR and AJCC stage IVB) (HR = 8.62, P = 0.003). The modified staging system incorporating NTR showed superior prognostic performance compared with the AJCC staging system.</p><p><strong>Conclusions: </strong>NTR is a significant independent prognostic factor for OS in node-positive HPSCC patients. Integrating NTR into the AJCC staging system improves prognostic accuracy.</p>","PeriodicalId":10692,"journal":{"name":"Clinical Nuclear Medicine","volume":" ","pages":"11-18"},"PeriodicalIF":9.6000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Nuclear Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/RLU.0000000000005544","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/17 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: The aim of this was to evaluate the prognostic significance of the nodal-to-primary tumor SUV max ratio (NTR) in patients with node-positive hypopharyngeal squamous cell carcinoma (HPSCC) treated with radiotherapy with or without concurrent chemotherapy. The study aims to enhance prognostic accuracy by incorporating NTR into the American Joint Committee on Cancer (AJCC) staging system.

Patients and methods: This retrospective study included 191 patients with biopsy-proven node-positive HPSCC treated from 2005 to 2013. NTR was calculated as the ratio of SUV max of metastatic lymph nodes to the primary tumor's SUV max . Survival analyses were conducted using Cox regression models and Kaplan-Meier analysis. Receiver operating characteristic analysis compared the prognostic performance of the modified and AJCC staging systems.

Results: The median follow-up was 8.27 years, with 135 deaths (70.7%). High NTR (≥0.63) was significantly associated with worse overall survival (OS) and was an independent prognostic factor in multivariable analysis (adjusted hazards ratio [HR] = 1.63, P = 0.007). Median OS for high NTR was 17.4 months, compared with 75.2 months for low NTR. High NTR significantly predicted worse OS within AJCC stage IVA patients (HR = 6.09, P = 0.014). Patients in modified stage IVA (AJCC stage IVA with low NTR) had significantly longer OS than those in modified stage IVB (AJCC stage IVA with high NTR and AJCC stage IVB) (HR = 8.62, P = 0.003). The modified staging system incorporating NTR showed superior prognostic performance compared with the AJCC staging system.

Conclusions: NTR is a significant independent prognostic factor for OS in node-positive HPSCC patients. Integrating NTR into the AJCC staging system improves prognostic accuracy.

淋巴结与原发肿瘤SUV比值在结节阳性下咽鳞状细胞癌放疗加或不加化疗治疗中的预后价值和临床意义
目的:本研究旨在评估结节阳性下咽鳞状细胞癌(HPSCC)患者在接受放疗并同时接受或不接受化疗的情况下,结节与原发肿瘤SUVmax比值(NTR)的预后意义。该研究旨在通过将 NTR 纳入美国癌症联合委员会(AJCC)分期系统来提高预后的准确性:这项回顾性研究纳入了 2005 年至 2013 年期间接受治疗的 191 例经活检证实为结节阳性的 HPSCC 患者。NTR以转移淋巴结的SUVmax与原发肿瘤的SUVmax之比计算。采用 Cox 回归模型和 Kaplan-Meier 分析法进行生存分析。接受者操作特征分析比较了改良分期系统和AJCC分期系统的预后效果:中位随访时间为8.27年,死亡135例(70.7%)。高NTR(≥0.63)与较差的总生存期(OS)显著相关,并且在多变量分析中是一个独立的预后因素(调整后危险比[HR] = 1.63,P = 0.007)。高NTR的中位OS为17.4个月,而低NTR为75.2个月。在AJCC IVA期患者中,高NTR明显预示着较差的OS(HR = 6.09,P = 0.014)。改良的IVA期(AJCC IVA期,低NTR)患者的OS明显长于改良的IVB期(AJCC IVA期,高NTR和AJCC IVB期)患者(HR = 8.62,P = 0.003)。与AJCC分期系统相比,包含NTR的改良分期系统显示出更优越的预后性能:结论:NTR是结节阳性HPSCC患者OS的重要独立预后因素。将 NTR 纳入 AJCC 分期系统可提高预后的准确性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Clinical Nuclear Medicine
Clinical Nuclear Medicine 医学-核医学
CiteScore
2.90
自引率
31.10%
发文量
1113
审稿时长
2 months
期刊介绍: Clinical Nuclear Medicine is a comprehensive and current resource for professionals in the field of nuclear medicine. It caters to both generalists and specialists, offering valuable insights on how to effectively apply nuclear medicine techniques in various clinical scenarios. With a focus on timely dissemination of information, this journal covers the latest developments that impact all aspects of the specialty. Geared towards practitioners, Clinical Nuclear Medicine is the ultimate practice-oriented publication in the field of nuclear imaging. Its informative articles are complemented by numerous illustrations that demonstrate how physicians can seamlessly integrate the knowledge gained into their everyday practice.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信